| Budget Amount *help |
¥26,390,000 (Direct Cost: ¥20,300,000、Indirect Cost: ¥6,090,000)
Fiscal Year 2011: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
Fiscal Year 2010: ¥9,490,000 (Direct Cost: ¥7,300,000、Indirect Cost: ¥2,190,000)
Fiscal Year 2009: ¥10,920,000 (Direct Cost: ¥8,400,000、Indirect Cost: ¥2,520,000)
|
|---|
| Research Abstract |
We generated NGR (Asn-Gly-Arg)-lipocalin-type prostaglandin D synthase (L-PGDS), possessing tumor-targeting NGR-motif, which specifically binds to CD13 receptor expressing in the endothelium of angiogenic blood vessels. NGR-L-PGDS was complexed with SN-38 which is a poorly water-soluble antitumor drug. The solubility of SN-38 in the presence of 2 mM NGR-L-PGDS in PBS increased by 300-fold as compared with that in PBS. Intravenous administration of SN-38/NGR-L-PGDS complex dominantly inhibited tumor growth as compared with control in mouse xenograft tumor model using human colon cancer cells.
|
